Latest Breaking News On - Amarin pharmaceuticals ireland - Page 1 : comparemela.com

Amarin Corporation plc: Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Amarin Corporation plc: Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesUnited arab emiratesNew jerseyGabriel stegColl cardiolPascalm burgerJohnr nelsonMichael millerHandrean sorenNabil abadirPeterp tothMark marmurJannickan dorresteijnDeepakl bhattClin cardiol

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,.

New jerseyUnited statesUnited arab emiratesNoord hollandPascalm burgerGabriel stegColl cardiolHandrean sorenJohnr nelsonMichael millerPeterp tothNabil abadirJannickan dorresteijnDeepakl bhattMark marmurClin cardiol

Amarin Corporation plc: Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism

United statesLoyola universityNew jerseyUnited arab emiratesMark marmurColl cardiolMarkg rabbatMohamad kassabNabil abadirClin cardiolLisa defrancescoFarouc jafferAmarin pharmaceuticals irelandJournal of the american college cardiologyAmerican heart associationExchange commission

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — Data Further Advances Understanding of VASCEPA/VAZKEPA. | May 12, 2023

United arab emiratesUnited statesNew jerseyLoyola universityClin cardiolNabil abadirFarouc jafferLisa defrancescoMohamad kassabMarkg rabbatMark marmurColl cardiolDrug administrationCorporate communicationsHead of global medical affairsResearch demonstrates multifactorial beneficial

Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing

Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without.

United statesNew jerseyUnited kingdomUnited arab emiratesGreat britainClin cardiolAmerican heart associationDrug administrationExchange commissionAmarin corporationEuropean unionAmarin pharmaceuticals irelandJournal of the american college cardiologyA report from the american heart associationPost hoc analysis showsReduced risk